FDA
-
-
-
-
-
-
-
NeuroOne(R) to Report First Quarter Fiscal Year 2026 Financial Results on Tuesday, February 17 at 8:30 a.m. Eastern Time
-
-
-
-
-
-
-
NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%
-
-
-
-
-
-
-
NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today’s Marketplace
-
-
-
-
-
-
-
NeuroOne® Product Revenue Increases 77% to $3.5 Million in Fiscal 2024: Expects Product Revenue to Increase at Least 132% to at Least $8 Million in Fiscal 2025
-
-
-
-
-
-
-
NeuroOne® Granted Approval of ICD-10 Procedure Code for sEEG RF Ablation
-
-
-
-
-
-
-
NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
NeuroOne® Provides Progress Update on FDA 510(k) Submission for OneRF™ Ablation System
-
334,504 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


